Unmatched Logistics Solutions for the Life Sciences Industry

Bringing Our Extensive Experience and Compliance Expertise to Your Global Supply Chain

425
Clinical Trials
3
Commercial Products
270,000+
Shipments
100+
Countries
q3-notification 

Upcoming Events View All

NOV11

BIO-Europe

Date: November 11 - 13, 2019
Location:Hamburg, Germany

DEC4

Cell Therapy Manufacturing & Gene Therapy Congress

Date: December 4 - 6, 2019
Location: Amsterdam, The Netherlands

The Latest From Our Blog View All

Avoiding Catastrophe: Addressing the Supply Chain Risks in Cell and Gene Therapy Development

There is no question that the groundbreaking treatments being developed in Cell & Gene Therapy (CGT) are fundamentally changing the way patient care is managed around the world. As with most revolutionary breakthroughs in medicine or any other industry, the supply chain is critically important. These revolutionary therapies only have value if you can effectively get them to the patients, or in the case of CGT, into the patient’s vein. Furthermore, CGT treatments are extremely fragile and require weeks to develop in multiple facilities. It cannot be stressed enough that a fail-proof supply chain is necessary.

VIDEO: Complying with Critical Regulations: Cryoport’s Chain of Compliance ™

Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. But the fragility of regenerative medicine therapies – and the need to more effectively manage risk– means that a fourth chain will soon be a regulatory requirement: the Chain of Compliance™. Enhanced traceability within the temperature-controlled and cold chain logistics distribution will soon be subjected to additional regulatory requirements due to the fragile aspect of the drug product and the disproportionate risk of improper cold chain management on the viability of the therapies.